Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk.

M. F. Linton, Sergio Fazio

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

It is now widely accepted that low-density lipoprotein (LDL) is not the only atherogenic component of the lipid profile and that abnormalities in the metabolism and plasma levels of triglycerides and high-density lipoprotein (HDL) may lead to accelerated growth of atherosclerotic lesions. Fibrates are the drugs of first choice in the management of hypertriglyceridemia, and are also able to substantially raise HDL. The recently published Veterans Administration-High-density Lipoprotein Intervention Trial (VA-HIT) trial showed that fibrate treatment in patients with coronary heart disease (CHD), low HDL, modestly elevated triglycerides, and normal LDL reduces the risk of a recurrent coronary event by 25%. A reasonable approach to the dyslipidemic patient with high CHD risk is to tailor the intervention to the specific lipoprotein abnormality. Under these assumptions fibrate therapy should become widespread, considering that the most common lipid alteration in CHD and patients with diabetes is low HDL and high triglycerides.

Original languageEnglish (US)
Pages (from-to)29-35
Number of pages7
JournalCurrent Atherosclerosis Reports
Volume2
Issue number1
StatePublished - Jan 2000
Externally publishedYes

Fingerprint

Fibric Acids
HDL Lipoproteins
Dyslipidemias
LDL Lipoproteins
Coronary Disease
Triglycerides
Lipids
United States Department of Veterans Affairs
Hypertriglyceridemia
Lipoproteins
Therapeutics
Growth
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk. / Linton, M. F.; Fazio, Sergio.

In: Current Atherosclerosis Reports, Vol. 2, No. 1, 01.2000, p. 29-35.

Research output: Contribution to journalArticle

@article{d935dc6264f84e9492ec909c8012ce82,
title = "Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk.",
abstract = "It is now widely accepted that low-density lipoprotein (LDL) is not the only atherogenic component of the lipid profile and that abnormalities in the metabolism and plasma levels of triglycerides and high-density lipoprotein (HDL) may lead to accelerated growth of atherosclerotic lesions. Fibrates are the drugs of first choice in the management of hypertriglyceridemia, and are also able to substantially raise HDL. The recently published Veterans Administration-High-density Lipoprotein Intervention Trial (VA-HIT) trial showed that fibrate treatment in patients with coronary heart disease (CHD), low HDL, modestly elevated triglycerides, and normal LDL reduces the risk of a recurrent coronary event by 25{\%}. A reasonable approach to the dyslipidemic patient with high CHD risk is to tailor the intervention to the specific lipoprotein abnormality. Under these assumptions fibrate therapy should become widespread, considering that the most common lipid alteration in CHD and patients with diabetes is low HDL and high triglycerides.",
author = "Linton, {M. F.} and Sergio Fazio",
year = "2000",
month = "1",
language = "English (US)",
volume = "2",
pages = "29--35",
journal = "Current Atherosclerosis Reports",
issn = "1523-3804",
publisher = "Current Medicine Group",
number = "1",

}

TY - JOUR

T1 - Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk.

AU - Linton, M. F.

AU - Fazio, Sergio

PY - 2000/1

Y1 - 2000/1

N2 - It is now widely accepted that low-density lipoprotein (LDL) is not the only atherogenic component of the lipid profile and that abnormalities in the metabolism and plasma levels of triglycerides and high-density lipoprotein (HDL) may lead to accelerated growth of atherosclerotic lesions. Fibrates are the drugs of first choice in the management of hypertriglyceridemia, and are also able to substantially raise HDL. The recently published Veterans Administration-High-density Lipoprotein Intervention Trial (VA-HIT) trial showed that fibrate treatment in patients with coronary heart disease (CHD), low HDL, modestly elevated triglycerides, and normal LDL reduces the risk of a recurrent coronary event by 25%. A reasonable approach to the dyslipidemic patient with high CHD risk is to tailor the intervention to the specific lipoprotein abnormality. Under these assumptions fibrate therapy should become widespread, considering that the most common lipid alteration in CHD and patients with diabetes is low HDL and high triglycerides.

AB - It is now widely accepted that low-density lipoprotein (LDL) is not the only atherogenic component of the lipid profile and that abnormalities in the metabolism and plasma levels of triglycerides and high-density lipoprotein (HDL) may lead to accelerated growth of atherosclerotic lesions. Fibrates are the drugs of first choice in the management of hypertriglyceridemia, and are also able to substantially raise HDL. The recently published Veterans Administration-High-density Lipoprotein Intervention Trial (VA-HIT) trial showed that fibrate treatment in patients with coronary heart disease (CHD), low HDL, modestly elevated triglycerides, and normal LDL reduces the risk of a recurrent coronary event by 25%. A reasonable approach to the dyslipidemic patient with high CHD risk is to tailor the intervention to the specific lipoprotein abnormality. Under these assumptions fibrate therapy should become widespread, considering that the most common lipid alteration in CHD and patients with diabetes is low HDL and high triglycerides.

UR - http://www.scopus.com/inward/record.url?scp=0033741188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033741188&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 29

EP - 35

JO - Current Atherosclerosis Reports

JF - Current Atherosclerosis Reports

SN - 1523-3804

IS - 1

ER -